natgillin/translations-raw huggingface dataset:
Darunavir/ritonavir 800/100 mg once daily in ART-experienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/ml or CD4+ cell count < 100 cells x 10 
Među bolesnicima prethodno liječenim ART-om, darunavir/ritonavir od 800/100 mg jedanput na dan ne smije se primjenjivati u bolesnika s jednom ili više mutacija povezanih s rezistencijom na darunavir (DRV-RAM) ili s HIV-1 RNK ≥ 100 000 kopija/ml ili brojem CD4+ stanica < 100 stanica x 10
Hence, concomitant use of darunavir coadministered with low dose ritonavir and the combination product lopinavir/ritonavir is contraindicated (see section 4.3). 
Odavde proizlazi da je istodobna primjena darunavira s niskom dozom ritonavira i kombiniranog lijeka lopinavira/ritonavira kontraindicirana (vidjeti dio 4.3).
darunavir/ ritonavir 600/100 mg twice daily N=298 
darunavir/ritonavir 600/100 mg dvaput na dan N=298
Darunavir co-administered with low dose ritonavir and amiodarone, bepridil, dronedarone, ivabradine, quinidine, or ranolazine is contraindicated (see section 4.3). 
Istodobna primjena darunavira istodobno primijenjenog s niskom dozom ritonavira i amiodarona, bepridila, dronedarona, ivabradina, kinidina ili ranolazina je kontraindicirana (vidjeti dio
General disorders and administration site conditions common asthenia, fatigue uncommon pyrexia, chest pain, peripheral oedema, malaise, feeling hot, irritability, pain rare chills, abnormal feeling, xerosis 
Nuspojava manje često pireksija, bol u prsištu, periferni edem, malaksalost, osjećaj vrućine, iritabilnost, bol rijetko zimica, nenormalno osjećanje, kseroza
Concomitant use of colchicine and darunavir co-administered with low dose ritonavir may increase the exposure to colchicine. 
Istodobna primjena kolhicina i darunavira primijenjenog istodobno s niskom dozom ritonavira može povećati izloženost kolhicinu. (inhibicija CYP3A i/ili P-gp-a)
It is not recommended to combine darunavir co-administered with low dose ritonavir with saquinavir. 
Ne preporučuje se istodobna primjena darunavira primijenjenog istodobno s niskom dozom ritonavira u kombinaciji sa sakvinavirom.
Abacavir Emtricitabine Lamivudine Stavudine Zidovudine 
Abakavir Emtricitabin Lamivudin Stavudin Zidovudin
Co-administration of boosted darunavir with dapoxetine is contraindicated. 
Istodobna primjena pojačanog darunavira s dapoksetinom je kontraindicirana.
Darunavir Krka 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen. 
Tablete Darunavir Krka od 400 mg i 800 mg mogu se uzimati za dostizanje jednokratne doze od 800 mg.
Darunavir co-administered with low dose ritonavir and atazanavir can be used without dose adjustments. 
Darunavir istodobno primijenjen s niskom dozom ritonavira i atazanavirom može se primijeniti bez prilagodbe doze.
concomitantly administered with boosted darunavir. 
Istodobna primjena kolhicina i pojačanog darunavira
The strong CYP3A inducers rifampicin and herbal preparations containing St John's wort (Hypericum perforatum). 
- kombinacija lijekova lopinavir/ritonavir (vidjeti dio 4.5). - snažni CYP3A induktori, rifampicin i biljni pripravci koji sadrže gospinu travu (Hypericum perforatum).
Darunavir Krka 400 mg film-coated tablets Darunavir Krka 800 mg film-coated tablets darunavir 
Darunavir Krka 400 mg filmom obložene tablete Darunavir Krka 800 mg filmom obložene tablete darunavir
Clinical monitoring is recommended when co-administering boosted darunavir with these analgesics. 
Preporučeno je kliničko praćenje kada se istodobno primjenjuju ovi analgetici s pojačanim darunavirom.
Darunavir Krka 400 mg film-coated tablets darunavir 
Darunavir Krka 400 mg filmom obložene tablete darunavir
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in 10 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 14 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 800/100 mg once daily (see section 4.2). 
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih jedanput na dan, u 10 pedijatrijskih prethodno liječenih bolesnika, u dobi od 3 do < 6 godina i težine najmanje 14 kg do < 20 kg, pokazala je da je doziranje temeljeno na težini rezultiralo izloženošću darunaviru, sličnoj onoj postignutoj u odraslih koji su uzimali darunavir/ritonavir 800/100 mg jedanput na dan (vidjeti dio 4.2).
Boosted darunavir and dolutegravir can be used without dose adjustment. 
Pojačan darunavir i dolutegravir mogu se uzimati bez prilagodbe doze.
Darunavir Krka 800 mg film-coated tablets darunavir 
Darunavir Krka 800 mg filmom obložene tablete darunavir
Darunavir is expected to increase these β-blocker plasma concentrations. 
Očekuje se da će darunavir povećati koncentracije tih β-blokatora u plazmi. (CYP2D6 inhibicija)
Concomitant use of everolimus and darunavir co-administered with low dose ritonavir is not recommended. 
Istodobna primjena everolimusa i darunavira istodobno primijenjenog s niskom dozom ritonavira se ne preporučuje.
Darunavir used in combination with cobicistat or low dose ritonavir once daily in ART-experienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/ml or CD4+ cell count < 100 cells x 10 
Darunavir koji se uzima u kombinaciji s kobicistatom ili niskom dozom ritonavira jedanput na dan, u ART-om prethodno liječenih bolesnika, ne smije se primjenjivati u onih bolesnika koji imaju jednu ili više mutacija povezanih s rezistencijom na darunavir (DRV-RAM, od engl. darunavir resistance associated mutations) ili HIV-1 RNK ≥ 100 000 kopija/ml ili broj CD4+ stanica < 100 stanica x 10
Dose for children 3 years of age and above, weighing more than 40 kilograms who have not taken antiretroviral medicines before (your child's doctor will determine this) The usual dose of Darunavir Krka is 800 milligram (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) together with 100 milligram ritonavir once daily. 
Doza za djecu u dobi od 3 godine i više, težine najmanje 40 kilograma koja nisu prethodno uzimala antiretrovirusne lijekove (to će odrediti liječnik Vašeg djeteta) - Uobičajena doza lijeka Darunavir Krka je 800 miligrama (2 tablete koje sadrže
Concomitant use of salmeterol and darunavir co-administered with low dose ritonavir is not recommended. 
Ne preporučuje se istodobna primjena salmeterola i darunavira primijenjenog istodobno s niskom dozom ritonavira.
Sildenafil to treat high blood pressure in the pulmonary circulation 
- sildenafil - kada se primjenjuje za liječenje plućne arterijske hipertenzije,
darunavir/ ritonavir 800/100 mg once daily N=294 
darunavir/ritonavir 800/100 mg jedanput na dan N=294
Yellowish brown, oval, biconvex film-coated tablets (tablets), engraved with a mark S1 on one side. 
Žućkastosmeđe, ovalne, bikonveksne filmom obložene tablete (tablete), s utisnutom oznakom S1 na jednoj strani.
Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with indinavir 800 mg twice daily. 
Darunavir: usporedba darunavira/ritonavira 400/100 mg dvaput na dan naspram darunavira/ritonavira 400/100 mg u kombinaciji s indinavirom 800 mg dvaput na dan.
ART-naïve paediatric patients from the age of 12 years to < 18 years, and weighing at least 40 kg DIONE is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with low dose ritonavir in 12 ART-naïve HIV-1 infected paediatric patients aged 12 to less than 18 years and weighing at least 40 kg. 
DIONE je otvoreno ispitivanje faze II koje je procijenilo farmakokinetiku, sigurnost, podnošljivost i djelotvornost darunavira s niskom dozom ritonavira u 12 pedijatrijskih bolesnika koji nisu prethodno liječeni ART-om, u dobi od 12 godina do < 18 godina i težine najmanje 40 kg.
Orangish brown, oval, biconvex film-coated tablets, engraved with a mark S2 on one side. 
Narančastosmeđe, ovalne, bikonveksne filmom obložene tablete, s utisnutom oznakom S2 na jednoj strani.
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 74 treatmentexperienced paediatric patients, aged 6 to 17 years and weighing at least 20 kg, showed that the administered weight-based doses of darunavir/ritonavir resulted in darunavir exposure comparable to that in adults receiving darunavir/ritonavir 600/100 mg twice daily (see section 4.2). 
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih dva puta na dan, u 74 prethodno liječena pedijatrijska bolesnika u dobi 6 do 17 godina i težinom najmanje 20 kg, pokazala je da primjena darunavira/ritonavira s doziranjem ovisnim o tjelesnoj težini rezultira izloženošću darunaviru koja je usporediva s onom u odraslih koji primaju darunavir/ritonavir od 600/100 mg dvaput na dan (vidjeti dio 4.2).
Amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine to treat certain heart disorders e.g. abnormal heart beat Lovastatin, simvastatin and lomitapide to lower cholesterol levels Rifampicin to treat some infections such as tuberculosis 
liječenje gihta ili obiteljske mediteranske vrućice lurasidon, pimozid, kvetiapin ili sertindol liječenje psihijatrijskih stanja ergot alkaloidi kao što su ergotamin, dihidroergotamin, ergometrin i metilergonovin liječenje migrenskih glavobolja amiodaron, bepridil, dronedaron, ivabradin, kinidin i ranolazin liječenje određenih srčanih poremećaja npr. abnormalni otkucaji srca lovastatin, simvastatin i lomitapid snižavanje razina kolesterola rifampicin liječenje nekih infekcija poput tuberkuloze kombinirani lijek lopinavir/ritonavir ovaj lijek protiv HIV-a pripada istoj skupini kao i Darunavir Krka elbasvir/grazoprevir liječenje infekcije hepatitisom C
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with darunavir coadministered with low dose ritonavir is required. 
Ako je potrebno liječenje darunavirom istodobno primjenjenim s niskom dozom ritonavira, preporučuje se smanjiti dozu kolhicina ili prekinuti liječenje kolhicinom u bolesnika s normalnom funkcijom bubrega ili jetre.
Unchanged darunavir accounted for approximately 41.2% and 7.7% of the administered dose in faeces and urine, respectively. 
41,2% odnosno 7,7% primijenjene doze darunavira može se naći u stolici, odnosno mokraći u nepromjenjenom obliku.
Rivaroxaban 
Rivaroksaban
darunavir/ ritonavir 600/100 mg twice daily N=296 
darunavir/ritonavir 600/100 mg dvaput na dan N=296
The Summary of Product Characteristics of ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with darunavir. 
Stoga se, prije početka terapije darunavirom, mora pročitati odgovarajući sažetak opisa svojstava za ritonavir.
Dose for adults who have taken antiretroviral medicines before (your doctor will determine this) Maybe you will require a different dose of Darunavir Krka which cannot be administered with these 400 or 800 milligram tablets. 
Možda ćete trebati drugačiju dozu lijeka Darunavir Krka koja se ne može primijeniti s ovim tabletama od 400 miligrama ili 800 miligrama.
For dosage recommendations in children see the Summary of Product Characteristics for Darunavir Krka 600 mg tablets.The dose of cobicistat to be used with darunavir has not been established in this patient population. 
Za preporučena doziranja u djece, vidjeti sažetak opisa svojstava lijeka za Darunavir Krka 600 mg tablete.
Instructions for children 3 years of age and above, weighing more than 40 kilograms Take 800 milligram Darunavir Krka (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) at the same time, once a day, every day. 
Upute za djecu od 3 godine i više, težine najmanje 40 kilograma - Uzmite 800 miligrama lijeka Darunavir Krka (2 tablete koja sadrže
Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration occurs. 
Kod istodobne primjene, mora se terapijski pratiti imunosupresivni lijek.
Darunavir is expected to increase these antipsychotic plasma concentrations. 
Očekuje se da će darunavir povećati koncentracije tih antipsihotika u plazmi. (CYP3A inhibicija)
Darunavir co-administered with low dose ritonavir and nevirapine can be used without dose adjustments. 
Darunavir istodobno primijenjen s niskom dozom ritonavira i nevirapinom može se primijeniti bez prilagodbe doze.
Data based on analyses at week 96 
Podaci temeljeni na analizama u 96. tjednu Pripisane vrijednosti izračunate prema TLOVR algoritmu
Concomitant use of darunavir coadministered with low dose ritonavir with lovastatin and simvastatin is therefore contraindicated (see section 
Istodobna primjena darunavira primijenjenog istodobno s niskom dozom ritonavira s lovastatinom i simvastatinom je zbog toga kontraindicirana (vidjeti dio 4.3).
HIV-1 RNA < 50 copies/ml CD4+ percent change from baseline CD4+ cell count mean change from baseline ≥ 1.0 log10 decrease from baseline in plasma viral load 
Srednja vrijednost promjene broja CD4+ stanica u odnosu na početni ≥ 1,0 log10 sniženje virusnog opterećenja plazme naspram početnih vrijednosti
darunavir/ritonavir 600/100 mg twice daily + OBR N=296 
darunavir/ritonavir 600/100 mg dvaput na dan + OBR N=296
When administration of rosuvastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety. 
Kada je potrebno primijeniti rosuvastatin i pojačan darunavir, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
For information on cobicistat, consult the cobicistat Summary of Product Characteristics. 
Za informacije o kobicistatu, pročitajte sažetak opisa svojstava lijeka za kobicistat.
Dapoxetine 
Paroksetin
Darunavir/ritonavir 800/100 mg once daily + OBR N=294 
Ishodi darunavir/ritonavir 800/100 mg jedanput na dan + OBR N=294
When administration of rosuvastatin and darunavir co-administered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety. 
Kada je potrebno primijeniti rosuvastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pritom pratiti sigurnost primjene.
cobicistat. 
ritonavira.
Co-administration with darunavir coadministered with cobicistat is not recommended (see section 4.4). 
Ne preporučuje se istodobna primjena s darunavirom istodobno primijenjenog s kobicistatom (vidjeti dio 4.4).
Yellowish brown, oval, biconvex film-coated tablets, engraved with a mark S1 on one side. 
Žućkastosmeđe, ovalne, bikonveksne filmom obložene tablete, s utisnutom oznakom S1 na jednoj strani.
Darunavir with low dose ritonavir may increase the exposure to grazoprevir. 
Darunavir s niskom dozom ritonavira može povećati
Boosted darunavir is expected to increase these β-blocker plasma concentrations. 
Očekuje se da će pojačan darunavir povećati koncentracije tih β-blokatora u plazmi. (CYP2D6 inhibicija)
The Summary of Product Characteristics of ritonavir must, therefore, be consulted prior to initiation of therapy with darunavir. 
Stoga se, prije početka terapije darunavirom, mora pročitati sažetak opisa svojstava lijeka za ritonavir.
With baseline CD4+ cell count < 
S početnim brojem CD4+ stanica < 200
600 milligram Darunavir Krka (1 tablet containing 600 milligram of Darunavir Krka) together with 100 milligram ritonavir twice daily. 
400 miligrama lijeka Darunavir Krka ili 1 tableta koja sadrži 800 miligrama lijeka Darunavir Krka) zajedno sa 100 miligrama ritnavira jednaput na dan.
Concomitant use of salmeterol and darunavir co-administered with low dose ritonavir may increase plasma 
Istodobna primjena salmeterola i darunavira primijenjenog istodobno s niskom dozom ritonavira može povećati koncentracije salmeterola u plazmi.
For further information on cobicistat, consult the cobicistat Summary of Product Characteristics. 
Za daljnje informacije o kobicistatu, pogledajte sažetak opisa svojstava lijeka za kobicistat.
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 14 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 15 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir /ritonavir 600/100 mg twice daily (see section 4.2). 
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih dvaput na dan, u 14 prethodno liječenih pedijatrijskih bolesnika u dobi 3 do < 6 godina s težinom najmanje 15 kg do < 20 kg, pokazala je da doziranje ovisno o tjelesnoj težini rezultira izloženošću darunaviru koja je usporediva s onom u odraslih koji primaju darunavir/ritonavir od 600/100 mg dvaput na dan (vidjeti dio 4.2).
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving Darunavir Krka. 
Majke koje primaju lijek Darunavir Krka se mora uputiti da ni pod kojim uvjetima ne doje zbog mogućeg prijenosa virusa HIV-a i zbog mogućih nuspojava u dojene dojenčadi.
Darunavir co-administered with low dose ritonavir and rilpivirine can be used without dose adjustments. 
Darunavir istodobno primijenjen s niskom dozom ritonavira i rilpivirinom može se primijeniti bez prilagodbe doze.
Artemether/lumefantrine (a combination medicine to treat malaria) Dasatinib, everolimus,irinotecan,nilotinib, vinblastine, vincristine (to treat cancer) Sildenafil, tadalafil, vardenafil (for erectile dysfunction or to treat a heart and lung disorder called pulmonary arterial hypertension) 
Ako se ne mogu primijeniti alternativni lijekovi, ovi lijekovi se smiju primjenjivati samo nakon medicinske procjene te uz pomni liječnički nadzor zbog nuspojava kortikosteroida. - buprenorfin/nalokson (lijekovi za liječenje ovisnosti o opioidima) - salmeterol (lijek za liječenje astme) - artemeter/lumefantrin (kombinirani lijek za liječenje malarije) - dasatinib, everolimus, irinotekan, nilotinib, vinblastin, vinkristin (za liječenje raka) - sildenafil, tadalafil, vardenafil (za liječenje erektilne disfunkcije ili srčanog i plućnog poremećaja koji se naziva plućna arterijska hipertenzija) - glekaprevir/pibrentasvir, simeprevir (za liječenje infekcije hepatitisom C) - fentanil, oksikodon, tramadol (za liječenje boli) - fesoterodin, solifenacin (liječenje poremećaja mokraćnog sustava).
Rare side effects (may affect up to 1 in 1,000 people) a reaction called DRESS [severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung] heart attack, slow heart beating, palpitations visual disturbance chills, feeling abnormal a feeling of confusion or disorientation, altered mood, restlessness fainting, epileptic fits, changes or loss of taste mouth sores, vomiting blood, inflamation of the lips, dry lips, coated tongue running nose skin lesions, dry skin stiffness of muscles or joints, joint pain with or without inflammation changes in some values of your blood cells or chemistry. 
- zimica, nenormalno osjećanje - osjećaj smetenosti ili dezorijentacije, promijenjeno raspoloženje, nemir - nesvjestica, epileptički napadaji, promjene ili gubitak okusa - ranice u ustima, povraćanje krvi, upala usnica, suhe usnice, obložen jezik - curenje nosa - oštećenja kože, suha koža - ukočenost mišića ili zglobova, bolovi u zglobovima s ili bez upale - promjene nekih vrijednosti stanica ili kemijskih nalaza u Vašoj krvi.
When administration of pravastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety. 
Kada je potrebno primijeniti pravastatin i pojačan darunavir, preporučuje se početi s najnižom mogućom dozom pravastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
Darunavir is expected to increase these antineoplastic plasma 
Očekuje se da će darunavir povećati koncentracije tih antineoplastika u plazmi. (CYP3A inhibicija)
Felodipine 
Klorazepat
Boosted darunavir and didanosine can be used without dose adjustments. 
Pojačan darunavir se može primijeniti s didanozinom bez prilagodbe doze.
Concominant administration of darunavir with low dose ritonavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3). 
Istodobna primjena darunavira s niskom dozom ritonavira i lurasidona, pimozida ili sertindola je kontraindicirana (vidjeti dio β-BLOKATORI Karvedilol Metoprolol Timolol
Darunavir co-administered with low dose ritonavir and raltegravir can be used without dose adjustments. 
Darunavir istodobno primijenjen s niskom dozom ritonavira i raltegravirom mogu se primijeniti bez prilagodbe doze.
Brownish red, oval, biconvex film-coated tablets (tablets), engraved with a mark S3 on one side. 
Smećkastocrvene, ovalne, bikonveksne filmom obložene tablete (tablete), s utisnutom oznakom S3 na jednoj strani.
Outcomes darunavir/ritonavir 600/100 mg twice daily + OBR N=298 
Ishodi darunavir/ritonavir 600/100 mg dvaput na dan + OOR N=298
It is not recommended to coadminister darunavir with low dose ritonavir and simeprevir. 
Ne preporučuje se istodobna primjena darunavira s niskom dozom ritonavira sa simeprevirom.
Clinical monitoring for central 
Neka klinička ispitivanja
administered with darunavir with low dose ritonavir resulting in the potential for increased adverse events usually associated with these agents. 
Koncentracije tih lijekova mogu se povećati kada se primjenjuju istodobno s darunavirom s niskom dozom ritonavira rezultirajući potencijalom za povećanje nuspojava obično povezanih s tim lijekovima.
The following patient populations were evaluated (see section 5.1): 80 ART-experienced HIV-1 infected paediatric patients aged from 6 to 17 years and weighing at least 20 kg who received darunavir tablets with low dose ritonavir twice daily in combination with other antiretroviral agents. 
- 80 pedijatrijskih bolesnika u dobi od 6 do 17 godina i težine najmanje 20kg, prethodno liječenih ART-om, a inficirani su virusom HIV-1 te su primali darunavir tablete s niskom dozom ritonavira dvaput na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
Boosted darunavir is expected to increase these antineoplastic plasma concentrations. 
Očekuje se da će pojačan darunavir povećati koncentracije tih antineoplastika u plazmi. (CYP3A inhibicija)
Darunavir co-administered with low dose ritonavir can be expected to increase the plasma concentrations of calcium channel blockers. 
Felodipin Nikardipin Nifedipin Verapamil dozom ritonavira može se očekivati da povisi koncentracije blokatora kalcijevih kanala u plazmi. (inhibicija CYP3A i/ili CYP2D6)
Co-administration of boosted darunavir and alfuzosin is contraindicated (see section 4.3). 
Istodobna primjena pojačang darunavira s alfuzozinom je kontraindicirana (vidjeti dio 4.3).
The recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food. 
Odrasli bolesnici prethodno liječeni antiretrovirusnom terapijom (ART-om) Preporučeni režim doziranja je 600 mg dvaput na dan uz 100 mg ritonavira dvaput na dan uzeto s hranom.